Abstract SNACC-54

Return to Poster Listing

Feasibility of Spatial Frequency Domain Imaging of Glioma Drug Delivery and Tumor Treatment Response

1Singh-Moon R, 2Roblyer D, 2Bigio I, 1Joshi S
1College of Physicians and Surgeons, Columbia University, New York, NY, USA; 2Boston University, Boston, MA, USA

Introduction: Spatial Frequency Domain Imaging (SFDI) is a specialized imaging method that permits wide-field, non-contact determination of tissue optical properties.(1-3) SFDI has previously been used to remotely determine biological properties of tissues such as hemoglobin and deoxy-hemoglobin content as well as extent of tumor infiltration in postmortem breast cancer specimens.(3) In C6 glioma tumor bearing Sprague Dawley rats, SFDI was used for quantification of tissue mitoxantrone (MTO) concentrations and values were compared to a previously-validated technique, the method of Optical Pharmacokinetics (OP).(4) Furthermore, also SFDI was used to map the extent infiltration of C6 glioma tumor implants and compared with tissue histology.

Method: For tumor MTO concentration measurements, studies with intraarterial (IA) mitoxantrone delivery were conducted one week after on C6 tumor implantation. Surgical preparation and drug delivery protocol was similar to that reported previously and it involved transient reduction in cerebral blood flow during IA injections of 0.5 mg of MTO.(5) Postmortem tissue samples were extracted from eight animals and tissue concentration of MTO were determined in the tumor and in the contralateral brain. Correlation between the two methods was determined by linear regression. In addition SFDI was used to determine tissue total hemoglobin content of tumor tissue and normal brain as well as light scattering and absorption parameters.
Results: Good correlation was seen between OP and SFDI determined MTO concentrations in the normal and tumor averaged sites Figure 1. Representative data from describing tumor light absorption and scattering is shown in Figure 2. Changes in reduced scattering seems to be most correlative with the hematoxylin-eosin stained tissue specimens demarcating the tumor edge.
Conclusions: This study shows the feasibility of mapping drug/tracer distributions and encourages the use of SFDI for spatial imaging of tissues for drug/tracer-tagged carrier deposition. Reduced scattering maps determined by SFDI could be useful for differentiating tumor margins in gross specimen to provide a rapid measurement of tumor dimensions. The study supports the role for SFDI in preclinical brain tumor research.

References:
1. D. J. Cuccia, F. et al., J Biomed Opt 14, 024012 (Mar-Apr, 2009).
2. D. J. Cuccia, F. et al., Optics letters 30, 1354 (Jun 1, 2005).
3. A. M. Laughney et al., Breast Cancer Res 15, (Aug, 2013).
4. R. Reif, et al., J Biomed Opt 12, 034036 (May-Jun, 2007).
5. S. Joshi et al., J Neurooncol, (Mar 25, 2014).

Acknowledgements: R01 CA 127500 and CA 138643

  • SNACC-54 Image 2
  • SNACC-54 Image 1

Back to Top